The ORR for QL1706 in advanced pretreated cervical cancer patients was 27.3% (15/55), and the mDoR was NR, with a median follow-up time of 7.5 (95% CI 7.2–8.2) months, which is comparable to dual PD-1 and CTLA-4 checkpoint blockade using the combination of balstilimab and zalifrelimab, which led to an ORR of 25.6% [37]. Here, CTLA4 is linked to cervical cancer.